Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Abiu Sempere und 19 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital Clínic-IDIBAPS & University of Barcelona, Hospital Clínic de Barcelona, Barcelona 08036, Spain. Hauptthemen laut MEDLINE: Triazoles, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit nennt 25 Literaturangaben. Gefördert von: MSD.
Abstract (Originalsprache)
Objectives
The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs).
Methods
DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks.
Results
Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed.
Conclusions
In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Hospital Clínic-IDIBAPS & University of Barcelona, Hospital Clínic de Barcelona, Barcelona 08036, Spain.
- Department of Medicine, University of Barcelona, Barcelona, Spain.
- Institut d'Investigacions Mèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Laboratori Clínic, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID-Profile: Lorena de la Mora, Alexy Inciarte, Leire Berrocal, Ana Gonzalez-Cordón, Elisa De Lazzari, María Martinez Rebollar, Berta Torres, Julia Calvo, Josep Mallolas, Alberto Foncillas, Esteban Martínez
Förderung
- MSD
Zitieren
APA
Sempere, A., de la Mora, L., Inciarte, A., Berrocal, L., Gonzalez-Cordón, A., Mosquera Cepeda, M. M., De Lazzari, E., Martinez Rebollar, M., Laguno, M., Torres, B., Chivite, I., Callau, P., Calvo, J., Ambrosioni, J., Mallolas, J., Foncillas, A., Miro, J. M., Rigo-Bonnin, R., Martínez, E., & Blanco, J. L. (2026). Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag297
Vancouver
Sempere A, de la Mora L, Inciarte A, Berrocal L, Gonzalez-Cordón A, Mosquera Cepeda MM, et al. Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag297
BibTeX
@article{Sempere2026,
author = {Sempere, Abiu and de la Mora, Lorena and Inciarte, Alexy and Berrocal, Leire and Gonzalez-Cordón, Ana and Mosquera Cepeda, María Mar and De Lazzari, Elisa and Martinez Rebollar, María and Laguno, Montserrat and Torres, Berta and Chivite, Ivan and Callau, Pilar and Calvo, Julia and Ambrosioni, Juan and Mallolas, Josep and Foncillas, Alberto and Miro, José María and Rigo-Bonnin, Raúl and Martínez, Esteban and Blanco, José Luis},
title = {Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag297}
}
EUVIMED